Effect of calcitriol and pamidronate in multiple myeloma

American Journal of the Medical Sciences

Volumn 318, Issue 1, 1999, Pages 61-66

  Imseis, Raed E ^a,d   Palmieri, Genaro M A ^a,e   Holbert, James M ^b   Leventhal, Marvin R ^a,c   Sebes, Jeno I ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b BAPTIST MEMORIAL HOSPITAL   (United States)

^c Campbell Clinic Memphis   (United States)

^d West Clinic ^*  (Jordan)

^e West Clinic   (United States)

Author keywords

Calcitriol; Multiple Myeloma; Pamidronate

Indexed keywords

CALCIFEDIOL; CALCITRIOL; CALCIUM CARBONATE; ERYTHROPOIETIN; HYDROCORTISONE; MELPHALAN; METHYLPREDNISOLONE; PAMIDRONIC ACID; SALCATONIN; VINCRISTINE;

ADULT; ARTICLE; BONE DENSITY; BONE LESION; BONE METASTASIS; BONE RADIOGRAPHY; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; HORMONE BLOOD LEVEL; HUMAN; MALE; MULTIPLE MYELOMA;

EID: 0033512238     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40574-9     Document Type: Article

References (40)

1. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484-9.
2. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657-64.
3. Hughes DE, Wright KR, Uy H, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
4. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia (England) 1998;12:200-29.
5. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
6. Tsoukas CD, Provvedini DM, Manolagas SC. 1,25-Dihydroxyvitamin D-3: a novel immunoregulatory hormone. Science 1984; 224: 1438-40.
7. Rigby EF, Noelle RJ, Krause K, et al. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: a cell cycle analysis. J Immunol 1985;135: 2279-86.
8. Amento EP, Bhalla AK, Kurnick JT, et al. 1,25-dihydroxyvitamin D3 induces maturation of the human monocyte cell line U937, and, in association with a factor from human T lymphocytes augments production of the monokine, mononuclear cell factor. J Clin Invest 1984;73:731-9.
9. Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 1983;62:709-21.
10. 3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 1981;102: 937-43.
11. 3-induced differentiation in a human promyelocytic leukemia cell line (HL60) receptor-mediated maturation to macrophage-like cells. J Cell Biol. 1984;98: 391-8.
12. Olsson I, Gullberg U, Ivhed I, et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1,25-dihydroxycholecalciferol. Cancer Res 1983;43:5862-7.
13. 3. Proc Natl Acad Sci U S A 1983;80: 5907-11.
14. 3 (calcitriol): a morphologic, phenotypic, and functional analysis. Blood 1984;64:1110-5.
15. 3 receptor. Cancer Res 1984;44:2103-2109.
16. 3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69:1399-407.
17. Zugmaier G, Jager R, Grage B, et al. Growth-inhibitory effects on vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 1996;73:1341-6.
18. 3 metabolite. Cancer Res 1983;43:4443-7.
19. 3, and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981; 108:1083-6.
20. 3, and its analogs on human colon adenocarcinoma cells (CaCo-2): Influence of extracellular calcium. Biochem Biophys Res Commun 1991;179:57-62.
21. 3 inhibits proliferation of human promyelocytic leukemia (HL-60) cells and induces monocytic-macrophage differentiation in HL-60 and normal bone marrow cells. Leuk Res 1983;7:51-5.
22. Colston KW, Chader SK, Mackay AG, et al. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992;44:693-702.
23. Eisman JA, Barkla DH, Tutton PJM. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 1987;47:21-5.
24. Cross HS, Pavelka M, Slavik J, et al. Growth control of human colon cancer cells by vitamin D and calcium in vitro. J Natl Cancer Inst 1992;84:1355-7.
25. Rossi JF, Durie BGM, Duperray C, et al. Phenotypic and functional analysis of 1,25-dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line RPMI 8226. Cancer Res 1988;48:1213-6.
26. 3 derivative, alone or in association with dexamethasone. Blood 1996;88:4659-66.
27. Atkinson SA, Fraher L, Gundberg CM, et al. Mineral homeostasis and bone mass in children treated for acute lymphoblastic leukemia. J Pediatr 1989;114:793-800.
28. Halton JM, Atkinson SA, Fraher L, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996;11: 1774-83.
29. Mawer EB, Walls J, Howell A, et al. Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab 1997;82:118-22.
30. Stack KM, Palmieri GMA. 1,25-dihydroxyvitamin D in severe immune challenges. Immunol Lett 1989;23:77.
31. Lawson-Matthew P, Clayton J, Guilland-Cumming D, et al. Vitamin D metabolism in myeloma. Br J Haematol 1989;73:57-60.
32. Palmieri, GMA. 1,25 dihydroxyvitamin D and cancer. J Clin Endocrinol Metab. 1997;82:3516.
33. 3 and the immune system. Mol Cell Endocrinol 1985;43:113-22.
34. 3 receptor in a cultured human breast cancer cell line (MCF-7). Biochem Biophys Res Commun 1980;93:9-15.
35. Rodriguez LH, Finkelstein JB, Shullenberger CC, et al. Bone healing in multiple myeloma with melphalan chemotherapy. Ann Intern Med 1972;76:551-6.
36. Sebes JI, Niell HB, Palmieri GMA, et al. Skeletal surveys in multiple myeloma. Radiological-clinical correlation. Skeletal Radiol 1986;15:354-9.
37. Mariette X, Bergot C, Rovaud P, et al. Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer 1995;76:1559-63.
38. Palmieri GMA, Pitcock JA, Brown P, et al. Effect of calcitonin and vitamin D in osteoporosis. Calcif Tissue Int 1989;45:137-41.
39. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 1990;113:649-55.
40. Tilyard MW, Spears GFS, Thomson J, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-62.